Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PARG | Q86W56 | 4/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17434617 | 0.95 | CYP1A2 (0.55) | CYP1A2KMT2AMAPTMEN1LMNA | |
| SCHEMBL17434620 | 0.86 | CYP1A2 (0.73) | CYP1A2KMT2AMAPTMEN1LMNA | |
| SCHEMBL17434092 | 0.86 | CYP1A2 (0.58) | CYP1A2KMT2AMAPTMEN1LMNA | |
| SCHEMBL17434558 | 0.82 | CYP1A2 (0.60) | CYP1A2KMT2AMAPTMEN1LMNA | |
| SCHEMBL17434118 | 0.81 | CYP1A2 (0.65) | CYP1A2KMT2AMAPTMEN1LMNA | |
| SCHEMBL17434259 | 0.81 | KDM4E (0.54) | KMT2AMAPTMEN1PARGPDE4A | |
| SCHEMBL17434506 | 0.81 | CYP1A2 (0.57) | CYP1A2KMT2AMAPTMEN1LMNA | |
| SCHEMBL17433905 | 0.80 | CYP1A2 (0.63) | CYP1A2KMT2AMAPTMEN1LMNA | |
| SCHEMBL17434573 | 0.80 | CYP1A2 (0.63) | CYP1A2KMT2AMAPTMEN1LMNA | |
| SCHEMBL17434445 | 0.80 | CYP1A2 (0.63) | CYP1A2KMT2AMAPTMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-2975031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | RORB, RORC, RORA | CYP1A2 159/4885KMT2A 234/4885MAPT 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.